Tuesday 9 May 2017, Amsterdam
This new report, now available on ASDReports, The Global Respiratory Inhalers Market, 2017-2027: Revenue prospects by Product Type (Metered Dose Inhalers, Dry Powder Inhalers, Nebulizers), By Indication (Asthma and COPD) and Geography 2017-2027 indicates that the Respiratory Inhalers market will see over $33bn in revenue in 2017.
The lead analyst of the report said:
“The advantages of inhalation therapy in the treatment of asthma and COPD have long since been established. In comparison to the oral and parenteral route, the drug dose required in inhalation therapy is lower and rapid onset of action is achieved with minimal unwanted systemic effects. The prevalence of asthma and COPD is growing across the globe and this is further fuelled by the growing ageing population. It is the major factor driving the growth of respiratory inhalers market. Other factors driving the market growth include technological advancements in respiratory inhalation products, growing awareness regarding respiratory diseases, and increasing disposable income in emerging economies.
However, growing pressure to reduce healthcare cost in the developed countries such as the U.S. is impeding the market growth. In addition, high cost of some types of inhalation devices (for instance, dry powder inhalers and nebulizers) is hindering the market growth in the respective product segments; especially in cost-sensitive markets. In addition to this, the market is likely to witness intense competition between generic and branded product manufacturers as some of the current blockbuster products are going off-patent across the forecast period. Thus, though sales will be increasing in terms of volume, the value market is likely to witness sluggish growth.”
ASDReports.com Media contact: S. Koopman -
Marketing and Communications
ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : firstname.lastname@example.org
back to News